Imunon, Inc. Common Stock (IMNN) Stock Price

IMNNStock

$1.02−79.84%52W

Market Cap$5.72M

P/E—

PEG Ratio5.03

Div yield—

Beta2.09

IMNN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-77.00%

Price vs S&P 500 (4W)-27.35%

PEG Ratio5.03

VGM Score41.45

Book Value / Share (Quarterly)$0.90

P/TBV (Annual)0.34x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.25

Price vs S&P 500 (YTD)-85.15%

Gross Margin (TTM)34.14%

Net Profit Margin (TTM)-6901.92%

EPS (TTM)$-4.42

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-4.42

EPS (Annual)$-1.58

ROI (Annual)-447.66%

Gross Margin (Annual)16.33%

Net Profit Margin (5Y Avg)-4275.20%

Cash / Share (Quarterly)$1.47

ROA (Last FY)-195.53%

EBITD / Share (TTM)$-3.70

ROE (5Y Avg)-173.69%

Operating Margin (TTM)-7361.54%

Cash Flow / Share (Annual)$-4.15

P/B Ratio1.37x

P/B Ratio (Quarterly)1.79x

Net Income / Employee (Annual)$-950,000

EV / Revenue (TTM)11.33x

Net Interest Coverage (TTM)-7.18x

ROA (TTM)-132.92%

EPS Incl Extra (Annual)$-1.58

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)1.44x

3-Month Avg Trading Volume0.13M

52-Week Price Return-79.84%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.94

P/S Ratio (Annual)11.45x

Asset Turnover (Annual)0.01x

52-Week High$5.29

Operating Margin (5Y Avg)-5140.80%

EPS Excl Extra (Annual)$-1.58

CapEx CAGR (5Y)69.59%

Tangible BV CAGR (5Y)51.40%

26-Week Price Return-67.10%

Quick Ratio (Annual)1.90x

13-Week Price Return-44.26%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.82x

Enterprise Value$5.89M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-29.83%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.35x

Pretax Margin (Annual)-7494.00%

Cash / Share (Annual)$2.57

3-Month Return Std Dev53.37%

Gross Margin (5Y Avg)33.75%

Net Income / Employee (TTM)$-735,800

ROE (Last FY)-447.66%

Net Interest Coverage (Annual)-123.74x

EPS Basic Excl Extra (Annual)$-1.58

P/FCF (TTM)0.95x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)1.68x

EPS Incl Extra (TTM)$-4.42

Receivables Turnover (Annual)0.00x

ROI (TTM)-228.80%

P/S Ratio (TTM)11.01x

Pretax Margin (5Y Avg)-4956.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.94

Price vs S&P 500 (52W)-95.37%

Year-to-Date Return-73.23%

5-Day Price Return-4.67%

EPS Normalized (Annual)$-1.58

ROA (5Y Avg)-90.30%

Net Profit Margin (Annual)-7180.00%

Month-to-Date Return-20.93%

Cash Flow / Share (TTM)$-3.05

EBITD / Share (Annual)$-1.56

Operating Margin (Annual)-7658.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-163.88%

LT Debt / Equity (Quarterly)1.32x

EPS Basic Excl Extra (TTM)$-4.42

P/TBV (Quarterly)0.34x

P/B Ratio (Annual)1.66x

Inventory Turnover (TTM)2.94x

Pretax Margin (TTM)-7203.85%

Book Value / Share (Annual)$2.07

Price vs S&P 500 (13W)-46.95%

Beta2.09x

P/FCF (Annual)2.53x

Revenue / Share (TTM)$0.00

ROE (TTM)-314.90%

52-Week Low$0.96

vGradeC

mGradeD

vgmGradeC

IMNN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.91	-$0.54	+40.66%(+$0.37)
Q1 2026	May 12, 2026	-$1.28	-$0.84	+34.20%(+$0.44)
Q4 2025	Mar 31, 2026	-$1.82	-$1.30	+28.57%(+$0.52)
Q3 2025	Nov 13, 2025	-$1.82	-$1.16	+36.36%(+$0.66)
Q2 2025	Aug 5, 2025	-$4.14	-$1.87	+54.86%(+$2.27)

IMNN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.10

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IMNNImunon, Inc. Common Stock	C	—	D	11.0x	—	34.1%	—	$1.02
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Imunon, Inc. Common Stock

Imunon Inc is a clinical-stage biotechnology company developing a non-viral DNA platform to treat various human diseases by leveraging the body's natural immune mechanisms. Its lead program, IMNN-001, is a DNA-based immunotherapy for ovarian cancer that has completed Phase II clinical trials. The company is also advancing IMNN-101, a COVID-19 booster vaccine candidate, currently in first-in-human studies.

IMNN Insider Transactions

SellAug 31, 2026
EYLWARD SUSAN
General Counsel
Shares: 2,525Value: $3,950
SellAug 17, 2026
EYLWARD SUSAN
General Counsel
Shares: 2,449Value: $3,993
SellAug 3, 2026
EYLWARD SUSAN
General Counsel
Shares: 2,541Value: $3,977

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

AIMAIM ImmunoTech Inc.Biological Products
BIOTInstinct Bio Technical Company Holdings Inc. Ordinary SharesCosmetics & Toiletries
TRIBTrinity Biotech plcIn Vitro Diagnostics
EVGNEVOGENE LTD.Agricultural Chemicals
GUREGulf Resources, Inc. (NV) Common StockChemicals
CELZCreative Medical Technology Holdings, Inc. Common StockBiological Products
VNRXVolitionRx LimitedIn Vitro Diagnostics
ORGNOrigin Materials, Inc. Common StockIndustrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$0.96

High$5.29